



2019 Beyond Type Run Team to Race the TCS New York City Marathon Using Basal-IQ Technology from Tandem Diabetes Care

November 1, 2019

SAN DIEGO--(BUSINESS WIRE)--Nov. 1, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, is supporting the efforts of Beyond Type 1, a global diabetes advocacy organization, in fielding its largest marathon team in history, made up of 30 runners with a combined 385 years of experience living with type 1 diabetes. The Beyond Type Run team will be running the TCS New York City Marathon on November 3, 2019, and Tandem Diabetes Care has made the t:slim X2™ insulin pump with Basal-IQ® technology available to all team members. A majority of the team chose to use the system for their personal diabetes management, training, and for the marathon.

"At Tandem, we believe in pushing the envelope and achieving extraordinary things," says John Sheridan, President and CEO of Tandem Diabetes Care. "The Beyond Type Run team exemplifies this spirit, and we are happy to support them with our advanced insulin delivery technology to help them do their best on race day."

Keary Cheney, a Beyond Type Run team member, diabetes advocate and mother of two, has been training with the t:slim X2 insulin pump with Basal-IQ technology for two months in preparation for the marathon. She is running for her daughter Zola, who was diagnosed with diabetes two months after her own diagnosis.

"Ever since the day that type 1 diabetes almost took my life, I have wanted to do more things that challenge me, that feel uncomfortable, that cause growth, and that push the limits. At some point I thought running 26.2 miles would do just that," said Cheney. "The t:slim X2 pump with Basal-IQ technology has radically changed the way I manage my diabetes during workouts and has made exercising a hundred times easier than when I used injections. Now I can't imagine running this race without it."

Beyond Type Run, co-captained by Rhone CEO and Co-founder Nate Checketts, and NASCAR driver Ryan Reed, will run through the five boroughs of New York City to inspire the more than 1.25 million Americans diagnosed with type 1 diabetes, a chronic, autoimmune disease.

Learn more about the full Beyond Type Run team at beyonddiabetes.org/beyond-type-run.

About Beyond Type 1

Beyond Type 1 (www.beyonddiabetes.org) is a nonprofit organization changing what it means to live with diabetes. Through platforms, programs, resources, and grants, Beyond Type 1 is uniting the global diabetes community and providing solutions to improve lives today. Founded in 2015 with a focus on education, advocacy and the path to a cure for Type 1 diabetes, Beyond Type 1 has grown to also include programs for those with Type 2 diabetes. A new model of philanthropy, Beyond Type 1 aims to change what it means to live with chronic illness.

About the t:slim X2 Insulin Pump with Basal-IQ Technology

The simple-to-use t:slim X2 insulin pump with Basal-IQ predictive low glucose suspend technology uses glucose values from an integrated Dexcom G6 continuous glucose monitor to predict and help prevent lows with zero fingersticks*. The t:slim X2 insulin pump includes advanced features like a large color touchscreen, rechargeable battery, Bluetooth® wireless technology, USB connectivity and watertight construction (IPX7)¹. It is capable of remote software updates using a personal computer, offering the potential for in-warranty users to access new features as they meet necessary regulatory requirements². The t:slim X2 insulin pump is up to 38 percent smaller than other insulin pumps and holds up to 300 units of insulin.³

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem's flagship product, the t:slim X2 insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.

Tandem Diabetes Care and Basal-IQ are registered trademarks, and t:slim X2 is a trademark of Tandem Diabetes Care, Inc. Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. The Bluetooth wordmark is a registered trademark owned by Bluetooth SIG, Inc. and any use of such mark by Tandem Diabetes Care, Inc. is under license. All other third-party marks are the property of their respective owners.

Important Safety Information for the t:slim X2 Insulin Pump with Basal-IQ Technology

Federal (USA) law restricts this device to sale by or on the order of a physician. The t:slim X2 insulin pump with Basal-IQ technology (the System) consists of the t:slim X2 insulin pump, which contains Basal-IQ technology, and a compatible CGM. CGM sold separately. The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The t:slim X2 insulin pump can be used solely for continuous insulin delivery and as part of the System. When the System is used with a compatible iCGM, Basal-IQ technology can be used to suspend insulin delivery based on CGM sensor readings. The System is indicated for use in individuals 6 years of

age and greater. The System is intended for single patient use and requires a prescription. The System is indicated for use with NovoLog/NovoRapid or Humalog U-100 insulin. The System is not approved for use in pregnant women, persons on dialysis, or critically ill patients. The pump is not intended for anyone unable or unwilling to: use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see their healthcare provider regularly. The user must also have adequate vision and/or hearing to recognize all functions of the pump, including alerts. For detailed indications for use and safety information, visit tandemdiabetes.com/safetyinfo.

* If glucose alerts and CGM readings do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. Dexcom G6 CGM sold separately.

¹ Tested to a depth of 3 feet for 30 minutes

² Additional feature updates are not currently available for the t:slim X2 insulin pump with Basal-IQ technology and are subject to future FDA approvals. A prescription and additional training may be required to access certain future software updates.

³ 38 percent smaller than MiniMed 630G and 670G and at least 28 percent smaller than MiniMed 530G, Animas Vibe and Omnipod System. Data on file, Tandem Diabetes Care.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191101005580/en/>

Source: Tandem Diabetes Care, Inc.

Tandem Diabetes Care Contact Information:

Media: Steve Sabicer, 714-907-6264, ssabicer@thesabicergroup.com

Investors: Susan Morrison, 858-366-6900 x7005, IR@tandemdiabetes.com